Establo Pharma sp. z o.o.

Manufacture of other food products not elsewhere classified

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2010-09-08
Share capital
250,000.00 PLN
Registered address
ul. Tokarska 13, 20-210 Lublin, Poland
Email
Phone
Electronic delivery address
AE:PL-61898-41696-DAUIC-15

Financials

Revenue history (in k)

Filing timeliness

3 of 6 financial statements were filed late (the longest delay 76 days for 2021).

  • 202517/07/2026
  • 202430/06/2025
  • 202315/07/2024
  • 202228/07/2023
  • 202129/09/2022
  • 202030/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Manufacture of food products244 / 764
Top 32%
Sector · Manufacturing3,047 / 11,953
Top 25%
City · Lublin716 / 4,835
Top 15%
Voivodeship · Lubelskie1,874 / 10,182
Top 18%
Country · Poland57,500 / 297,566
Top 19%

Results vs industry

Revenue
This companyUSD 2.20mMedianUSD 266.78kAverageUSD 5.34m
Net profit
This companyUSD 210.13kMedianUSD 2.11kAverageUSD 362.76k
Operating costs
This companyUSD 1.94mMedianUSD 276.57kAverageUSD 4.73m
Assets
This companyUSD 1.96mMedianUSD 219.08kAverageUSD 4.07m

Websites

The company has 12 websites. Most of them run on WordPress. The sites are available in: Polish and English. The sites target these markets: United States. The company measures traffic with Google Analytics and uses the Meta advertising pixel (Facebook, Instagram).

  • establopharma.comEstablo Pharma Sp. z o.o.
    WordPressElementorGoogle AdsGoogle AnalyticsGoogle Tag ManagerLiteSpeed
  • composita.plComposita One i Composita Mama DHA – Wsparcie dla zdrowia kobiet
    WordPress 7.1ElementorGoogle AdsGoogle AnalyticsGoogle Tag ManagerLiteSpeed
  • ellabiom.plEllabiom® – probiotyk i prebiotyk dla kobiet | 11 szczepów bakterii – Ellabiom® to wsparcie mikrobiomu przy infekcjach intymnych, po antybiotykoterapii i w IBS. Probiotyk + prebiotyk w jednej kapsułce. Dla kobiet, które chcą czuć się lepiej.
    WordPress 7.1ElementorGoogle AnalyticsGoogle Tag ManagerLiteSpeed

Trademarks

The company holds 9 active trademarks registered with the Polish Patent Office. The first mark was filed in 2014.

MarkNumberClassesStatusProtected until
Endoprofem Z.5532825Protected Mar 6, 2033
inofem Activ Z.4983545, 30Protected Apr 8, 2029
inofem Duo Z.4983535, 30Protected Apr 8, 2029
DIABEROL CONTROL Z.4924645Protected Nov 8, 2028
SUPRAMEN Z.4924655Protected Nov 8, 2028
MarkProtected until
Endoprofem Mar 6, 2033
inofem Activ Apr 8, 2029
inofem Duo Apr 8, 2029
DIABEROL CONTROL Nov 8, 2028
SUPRAMEN Nov 8, 2028

Job offers

The company currently has 3 active job offers at public employment offices. 5 offers were posted in the last 12 months.

PositionAdded
Finance and Office Administrator20 Oct 2026
Accountant and Finance and HR Clerk19 Oct 2026
Manual Packer7 Oct 2026

Authorized Representatives

Michał Jakub Kołodziński age 46 – Management Board Member
Szymon Jakub Sikora-Zachariasz age 44 – Management Board Member

Manner of representation

The management board represents the company externally and manages its day-to-day operations. Each member of the management board is entitled to represent the company independently.

Ownership

OwnerSharesShare valueStake
18$24,311.1836%
18$24,311.1836%
Others
14$18,908.7028%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2010-10-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

28 public aid cases recorded, with a total value of $612,158.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$6,991
Aid for SME participation in trade fairs
$61,426
De minimis aid (in accordance with Commission Regulation 2023/2831)
$41,275

European Funds

ProjectEU co-financing
Developing exports of the Polish INOFEM brand in the Middle East and Asian markets.
$102.7K
Implementation of an internationalisation business model for Establo Pharma Sp. z o.o. in foreign markets.
$102.6K
Development of a business internationalisation model for ESTABLO PHARMA SP. Z O.O.
$8,886

Competitors

Name
Hemplab sp. z o.o.
Komarko sp. z o.o.
AG Pharm sp. z o.o.
CFP Investment sp. z o.o.
Bioticom sp. z o.o.
Biocorpo sp. z o.o.
Noblepharma sp. z o.o.
Pharma Dot sp. z o.o.
Auralab360 sp. z o.o.
Bionatur sp. z o.o. + limited partnership

Change history

DateEvent
2025-02-06Address change
2020-05-18Address change
2017-09-07PKD change
2014-09-23Address change
2014-04-15Share capital increase

FAQ

Last updated: 2026-07-17